Company Description: The current drug development process does not capture cancer complexity or heterogeneity. This is a main reason why 96% of drugs fail when they meet patients in clinical trials, lacking efficacy in the patient population. Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development. Their cutting-edge approach involves the integration of functional testing and AI-powered analysis, leveraging top-tier biology alongside comprehensive clinical and molecular data. As a spin-out from Gustave Roussy, the 1st cancer center in Europe, Orakl’s boasts unique access to a vast repository of patient tissue samples and associated data. This strategic foundation positions them to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers. The founders, Fanny jaulin (CEO/CSO), Diane-Laure Pagès (COO), and Gustave Ronteix (CTO), collectively bring unparalleled expertise in cancer cell biology and engineering. With over 30 years of combined academic experience across France, the UK, and the US, the team is dedicated to improving cancer research. For more information, please visit www.orakl-oncology.com